# GE Healthcare invests $80M to expand contrast media API capacity in Norway

GE Healthcare's Pharmaceutical Diagnostics business announced an $80 million investment to increase manufacturing capacity by 30% at its Active Pharmaceutical Ingredients site in Lindesnes, Norway, creating about 100 new jobs. The expansion aims to enable production of 30 million more patient doses per year by 2025.

- Type: Expansion
- Announced: 2022-11-17
- Where: Lindesnes, Norway, Norway
- Value: $80.0M
- Jobs: 100
- Starts operating: 2025
- Status: announced
- Capacity: 30% increase in manufacturing capacity; 30 million more patient doses per year
- Products: iodinated contrast media, iohexol API, iodixanol API
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [GE Healthcare](https://endata.com/companies/4246.md)

## Sources

- [businesswire.com](https://www.businesswire.com/news/home/20221117005624/en/GE-Healthcare-Announces-%2480-Million-Investment-To-Expand-Contrast-Media-Production-Capacity), 2022-11-17: "This investment in capacity expansion at our Lindesnes facility is another example of how we, as an industry leader, are addressing this growing demand to meet the needs of our customers and their patients across the globe."
- [appliedradiology.com](https://www.appliedradiology.com/news/ge-to-invest-80-million-to-expand-contrast-media-production-capacity), 2022-11-18: "We expect global demand for iodinated contrast media to double in the next 10 years, driven by global prevalence of chronic disorders and significant growth in CT procedures."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.